Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,621 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Non-Insulin Dependent Clear all
Completed Phase 3 Interventional

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

NCT00106340
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, glimepiride, Metformin, Vildagliptin matching placebo, Glimepiride matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 73 Years
Enrollment
3,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

NCT02390050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bexagliflozin tablets, Bexagliflozin tablets, placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Peoria, Arizona • Tucson, Arizona • Canoga Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 9, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Glucose Control in Patients With Diabetes

NCT04230889
View directory record Official record
Conditions
Glycemic Control
Interventions
Usual Diet Group, Group 1 Nutritional Shake, Group 2 Nutritional Shake
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
30 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Boca Raton, Florida • Pinellas Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 9, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:

NCT04820348
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Depression, Anxiety, Diet Habit
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 9, 2026, 11:42 AM EDT
Recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 9, 2026, 11:42 AM EDT
Recruiting Phase 2 Interventional

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484
View directory record Official record
Conditions
Type 2 Diabetes, Cortisol Excess
Interventions
clofutriben, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
61
States / cities
Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

NCT02964247
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 9, 2026, 11:42 AM EDT
Completed No phase listed Observational

Periodontal Treatment Response in Type II Diabetic Patients

NCT01881074
View directory record Official record
Conditions
Type II Diabetes, Periodontal Disease
Interventions
Triclosan containing toothpaste, Non-triclosan containing toothpaste
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 9, 2026, 11:42 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
33
States / cities
Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 9, 2026, 11:42 AM EDT
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 9, 2026, 11:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Appetite Self-Regulation in African American Adults With Type 2 Diabetes

NCT05741125
View directory record Official record
Conditions
Type 2 Diabetes, Binge Eating
Interventions
DSME + ASE intervention (Centering Appetite)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes

NCT00795691
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
low-carbohydrate diet, low-fat diet
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 9, 2026, 11:42 AM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PREMIER: PREvention of Metabolic Illness Through prEcision nutRition

NCT04148482
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Metabolic Syndrome, Diet Habit, Nutritional and Metabolic Disease, Food Preferences
Interventions
Dietary intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 4 Interventional

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

NCT00035568
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), or Metformin HCl alone, or Glyburide alone.
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 9, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Results available

Hypogonadism in Young Men With Type 2 Diabetes

NCT01155518
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions
testosterone, clomiphene, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

NCT00839527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
321
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 9, 2026, 11:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

NCT02537470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
Biphasic Remogliflozin Etabonate, Placebo
Drug · Other
Lead sponsor
BHV Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 9, 2026, 11:42 AM EDT